+499.5%
MRNA vs AVAV
-39.1%
+538.5%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | AVAV | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | -1.7% | -0.5% | -1.9% |
| 7D | +5.5% | -2.2% | +7.7% | +5.9% |
| 30D | +158.7% | -13.9% | +172.7% | +167.2% |
| 3M | +182.1% | -29.2% | +211.4% | +199.8% |
| 6M | +151.8% | -36.1% | +187.9% | +169.3% |
| YTD | +393.6% | -40.2% | +433.8% | +404.7% |
| 1Y | +499.5% | -36.2% | +535.7% | +428.4% |
| All | +499.5% | -39.1% | +538.5% | +428.4% |
Cumulative growth
Daily Returns
Daily percentage return beside AVAV.
Daily Out/Under-Performance
Portfolio return minus AVAV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × AVAV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded AVAV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling